Podcast

Off Our Chests: An Oncologist Turned Caregiver and His Wife Share Their Cancer Journey From All Angles

Author(s):

Dr. John Marshall and his wife, Liza, look back on the trials and tribulations of Liza’s triple-negative breast cancer diagnosis – from the perspective of a patient and her husband, the caregiver and oncologist.

One pair – Dr. John Marshall and his wife, Liza – have been surrounded by cancer since John became an oncologist early on in their marriage. The duo never imagined the disease would dramatically change their world when Liza was diagnosed with stage 3 triple-negative breast cancer.

John was without a doubt impacted by the unexpected diagnosis as he had to learn how to juggle between playing a caregiver and being a doctor at the same time, while Liza, the matriarch of the family who was always in charge of her own health, leaned on her husband for support and medical advice.

In the book “Off our Chests: A Candid Tour Through the World of Cancer,” both John and Liza Marshall alternate sharing their perspectives on this challenging time. CURE and OncLive sat down with John and Liza to go beyond the pages in the book, as the couple discussed their journey – both together and separately – as well as the deep appreciation they now have for other, patients and their oncologists.

“Off Our Chests: A Candid Tour Through the World of Cancer” will be released in hardcover format on April 6, 2021. Visit: https://www.amazon.com/Off-Our-Chests-Candid-Through/dp/1646870484.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.